Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 2 of 15

→ The Long-Awaited End of America Update (From Stansberry Research) (Ad)
Slide 2
Back to 1
Continue to 3
 
Back to 1
Continue to 3
 

Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$133.60 (7.7% Upside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
4/12/2024BMO Capital MarketsInitiated CoverageOutperform$163.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
3/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/1/2024Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$120.00 ➝ $140.00
1/23/2024Morgan StanleyInitiated CoverageOverweight$120.00
1/16/2024UBS GroupInitiated CoverageNeutral
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
Slide 2
Back to 1
Continue to 3
 

Urgent dollar warning (Ad)

Your 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.

Find out for free here.

More From MarketBeat
Biden to Launch “FedNOW” [Move Your Money Now]
from Priority Gold
7 Stocks That Members of Congress Can’t Stop Buying
from MarketBeat
AI finds its first serious application
from Wall Street Star
7 High-Yield Dividend Stocks to Beat Fixed-Income Yields
from MarketBeat
Healthcare Takes A Big Step Forward With The Help Of AI
from The Bull Report
10 Rock-Solid Dividend Paying Stocks to Add to Your Portfolio
from MarketBeat